NasdaqCM - Delayed Quote USD

Apollomics, Inc. (APLMW)

0.0085
-0.0065
(-43.33%)
At close: May 9 at 4:00:00 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for APLMW

Recent News: APLMW

View More
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
GlobeNewswire last month
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib
GlobeNewswire last month
Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia
GlobeNewswire 4 months ago
Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
GlobeNewswire 4 months ago
Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split

Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split
GlobeNewswire 5 months ago
Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024

Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024
GlobeNewswire 7 months ago
Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
GlobeNewswire 8 months ago
Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
GlobeNewswire 8 months ago
Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial
GlobeNewswire 8 months ago
Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference

Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference
GlobeNewswire 8 months ago
Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement
GlobeNewswire 9 months ago
View More

Related Tickers

SRZNW Surrozen, Inc.
0.0230
0.00%
 
PTIXW Protagenic Therapeutics, Inc.
0.0073
-1.35%
 
TCBWF TC Biopharm (Holdings) Plc
0.0089
0.00%
 
KLTOW Klotho Neurosciences, Inc.
0.0159
+1.92%
 
COEPW Coeptis Therapeutics Holdings, Inc.
0.0296
+18.88%
 
WINTW WINDTREE THERAPEUTICS INC C/WTS
0.0070
+100.00%
 
KMSTF Kadimastem Ltd
5.06
0.00%
 
DRMAW Dermata Therapeutics, Inc.
0.0249
0.00%
 
OSRHW OSR Holdings, Inc.
0.0313
-28.86%
 
NLSPW NLS Pharmaceutics AG
0.0097
+136.59%